Contact Us
Drug Search Results
More Filters [+]

AVX-420

Alternative Names: AVX-420, AVX420, AVX 420
Latest Update: None
Latest Update Note: None

Product Description

Our drug candidate AVX420 is a molecule that blocks the enzyme cPLA2alpha that plays a key role in the development of cancer and inflammation. AVX420 has shown promising results in several preclinical models for leukemia. What is unique about AVX420 is that the molecule attacks the cancer in multiple ways. (Sourced from: https://www.coeginpharma.com/en/our-research/projects/leukemia/)

Mechanisms of Action: cPLA2a Blocker

Novel Mechanism: Yes

Modality: N/A

Route of Administration: N/A

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Coegin
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for AVX-420

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 0: Leukemia

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Recent News Events

Date

Type

Title

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions